Literature DB >> 23386229

Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.

David Alexander Sclar, Linda M Robison, Ambartsum M Oganov, Jennifer M Schmidt, Kurt A Bowan, Leigh V Castillo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23386229     DOI： 10.1007/s40261-013-0059-z

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  3 in total

1.  Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.

Authors:  James Greig
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

2.  The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.

Authors:  Judith A O'Brien; Betsy J Lahue; J Jaime Caro; David M Davidson
Journal:  Infect Control Hosp Epidemiol       Date:  2007-10-03       Impact factor: 3.254

3.  Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.

Authors:  David Alexander Sclar; Linda M Robison; Ambartsum M Oganov; Jennifer M Schmidt; Kurt A Bowen; Leigh V Castillo
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.